229 related articles for article (PubMed ID: 20110034)
1. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
Obradovic M; Mrhar A; Kos M
Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
[TBL] [Abstract][Full Text] [Related]
2. Accessibility to targeted oncology drugs in Slovenia and selected European countries.
Kos M; Obradovic M; Mrhar A
Eur J Cancer; 2008 Feb; 44(3):408-18. PubMed ID: 18155900
[TBL] [Abstract][Full Text] [Related]
3. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
4. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
Kocs D; Fendrick AM
Am J Manag Care; 2003 May; 9(5):393-400; quiz 401-2. PubMed ID: 12744301
[TBL] [Abstract][Full Text] [Related]
5. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
Altagracia-MartÃnez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
[TBL] [Abstract][Full Text] [Related]
6. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the pharmaceuticals market and its technological development in Turkey.
Kisa A
Int J Technol Assess Health Care; 2006; 22(4):537-42. PubMed ID: 16984690
[TBL] [Abstract][Full Text] [Related]
8. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
9. New chemical entities and their market penetration in Finland during the years 1996 through 2005.
Martikainen JE; Enlund H
Clin Ther; 2009 Mar; 31(3):668-76. PubMed ID: 19393857
[TBL] [Abstract][Full Text] [Related]
10. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
11. Postmarket policy considerations for biosimilar oncology drugs.
Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
[TBL] [Abstract][Full Text] [Related]
12. Loading doses for costly cancer biologicals: sound pharmacology or unnecessary extravagance?
Epstein RJ; Cheung BM
Eur J Cancer; 2008 Jul; 44(11):1488-92. PubMed ID: 18194858
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
Lexchin J
Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
Dylst P; Vulto A; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
[TBL] [Abstract][Full Text] [Related]
16. Projecting future drug expenditures--1994.
Santell JP
Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
[TBL] [Abstract][Full Text] [Related]
17. Market watch: Sales of biologics to show robust growth through to 2013.
Goodman M
Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
[No Abstract] [Full Text] [Related]
18. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
19. International variation in prescribing antihypertensive drugs: its extent and possible explanations.
Fretheim A; Oxman AD
BMC Health Serv Res; 2005 Mar; 5(1):21. PubMed ID: 15762983
[TBL] [Abstract][Full Text] [Related]
20. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
Looper YJ
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
